Drägerwerk AG & Co KGaA: A Triumph of Order Growth, Record Sales, and Unrelenting Dividend Acceleration
The German health‑care equipment powerhouse has delivered a fiscal‑year performance that is not merely good, but audacious. In 2025, Drägerwerk achieved a record net sales figure, boosted by simultaneous growth across its two principal divisions and every geographic region it serves. This growth has been sustained despite a backdrop of difficult economic conditions, a fact that underscores the company’s resilient business model.
Order Intake Surpasses a Record High
The company’s order intake eclipsed the already lofty figures of the previous year. This surge in demand demonstrates a robust pipeline that will likely translate into continued revenue expansion in the coming fiscal period. Investors who have been watching Drägerwerk’s order book can now see that the company is not just maintaining momentum—it is accelerating.
EBIT Climbs by 20 % in a Challenging Environment
While many peers have struggled to keep profitability steady, Drägerwerk’s EBIT has risen by roughly 20 %. Such a leap in earnings before interest and taxes—achieved amid global supply‑chain frictions, regulatory tightening, and rising input costs—speaks to the firm’s operational excellence and cost‑management acumen. The company has therefore proven that it can convert higher sales into meaningful profitability gains.
Dividend Policy: A Third Straight Increase
Drägerwerk’s dividend policy reflects its confidence in sustained earnings. For the 2025 year, the board declared a higher dividend of EUR 2.21 per common share (up from EUR 1.97 in 2024) and EUR 2.27 per preferred share (up from EUR 2.03). This marks the third consecutive dividend increase—a testament to the company’s solid cash‑flow generation and its willingness to reward shareholders consistently.
Market Valuation and Investor Return
The company’s market capitalisation sits at €1.372 bn, with a P/E ratio of 10.954—a figure that suggests the stock is priced within a reasonable valuation envelope given its robust growth trajectory. The share price on 2026‑03‑22 closed at €69.40, comfortably above the 52‑week low of €46.5 and within reach of the 52‑week high of €76. Over the past decade, an investment of €1 000 in Drägerwerk at its XETRA listing price of €59.40 (2021‑03‑20) would now be worth €1 437.71—a 43.77 % return, excluding splits and dividends.
A Call to Action
For the discerning investor, Drägerwerk’s combination of record sales, expanding order intake, robust profitability, and a disciplined dividend policy spells an attractive value proposition. The company’s performance demonstrates that disciplined execution, coupled with strategic market positioning, can yield consistent outperformance even when macro conditions are less than favourable.
In short, Drägerwerk AG & Co KGaA is not just surviving in a competitive landscape—it is thriving. The evidence is clear: the company’s financials, its growth metrics, and its shareholder‑friendly dividend strategy all point to a firm that is ready to deliver sustained value.
